11 employees
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
2016
$40M
from 2 investors over 2 rounds
Dracen Pharmaceuticals, Inc. raised $40M on March 22, 2018
Investors: i&i Prague and Osage University Partners (OUP)